Los Angeles Capital Management LLC Dynavax Technologies Corp Transaction History

Los Angeles Capital Management LLC

$27.9 Billion
Q2 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$13.09 - $14.98 $202,868 - $232,160	-15,498 Reduced 19.55%	63,774 $891,000
Q3 2023 Nov 06, 2023	BUY	$12.64 - $14.99 $21,475 - $25,468	1,699 Added 2.19%	79,272 $1.17 Million
Q2 2023 Aug 03, 2023	SELL	$9.85 - $13.17 $38,483 - $51,455	-3,907 Reduced 4.8%	77,573 $1 Million
Q1 2023 May 04, 2023	SELL	$9.44 - $11.88 $11,601 - $14,600	-1,229 Reduced 1.49%	81,480 $799,000
Q4 2022 Feb 06, 2023	BUY	$10.27 - $13.29 $389,007 - $503,398	37,878 Added 84.49%	82,709 $880,000
Q3 2022 Nov 02, 2022	BUY	$9.93 - $17.44 $280,264 - $492,226	28,224 Added 169.95%	44,831 $468,000
Q2 2022 Aug 05, 2022	SELL	$7.45 - $12.83 $16,471 - $28,367	-2,211 Reduced 11.75%	16,607 $209,000
Q1 2022 May 06, 2022	BUY	$9.75 - $14.44 $183,475 - $271,731	18,818 New	18,818 $204,000
Q4 2021 Feb 03, 2022	SELL	$13.17 - $20.94 $762,345 - $1.21 Million	-57,885 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$9.16 - $19.83 $306,493 - $663,511	-33,460 Reduced 36.63%	57,885 $1.11 Million
Q2 2021 Aug 05, 2021	SELL	$7.25 - $10.99 $329,795 - $499,924	-45,489 Reduced 33.24%	91,345 $900,000
Q1 2021 May 05, 2021	BUY	$4.57 - $11.18 $467,611 - $1.14 Million	102,322 Added 296.48%	136,834 $1.35 Million
Q4 2020 Feb 04, 2021	BUY	$3.73 - $5.6 $128,729 - $193,267	34,512 New	34,512 $154,000
Q3 2018 Nov 05, 2018	SELL	$11.85 - $16.0 $129,508 - $174,864	-10,929 Closed	0 $0
Q2 2018 Jul 31, 2018	SELL	$15.15 - $20.75 $76,189 - $104,351	-5,029 Reduced 31.51%	10,929 $167,000
Q1 2018 Apr 27, 2018	BUY	$14.65 - $19.9 $233,784 - $317,564	15,958 New	15,958 $317,000

Others Institutions Holding DVAX

# of Institutions

257

Shares Held

132M

Call Options Held

371K

Put Options Held

99.2K

View Full List

About DYNAVAX TECHNOLOGIES CORP

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.44B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

More about DVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.

Account